Educational Resource · 2026
CAR-T Cell Therapy in Turkey:
Access, Costs & the Emerging Landscape
An independent guide to chimeric antigen receptor T-cell therapy. Understand how the treatment works, compare global access and costs, and learn about local manufacturing through technology transfer.
Living Medicine
CAR-T · Personalized Cellular Therapy
What is CAR-T Cell Therapy?
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalized cellular immunotherapy. A patient’s own T cells are collected, genetically engineered in a specialized laboratory to recognize a specific marker on cancer cells, expanded, and then returned to the patient as a living medicine.
In many B-cell lymphomas and leukemias the target marker is CD19. Once infused, the engineered cells can expand, seek out CD19-positive cells, and exert cytotoxic activity. Unlike conventional drugs, CAR-T cells are living cells whose behavior depends on both product design and the individual patient’s biology.
The treatment is typically considered for patients whose disease has relapsed or become refractory after standard therapies.
Full explanation of CAR-T therapyKey characteristics
- 01 Autologous — made from the patient’s own cells in most current commercial products
- 02 One-time (or limited) infusion after lymphodepleting chemotherapy
- 03 Requires specialized manufacturing, quality control and hospital monitoring
- 04 Main established indications: certain relapsed/refractory B-cell lymphomas and leukemias
- 05 Expanding investigation in other diseases, including some autoimmune conditions
The CAR-T process at a glance
From evaluation to long-term follow-up — the typical pathway for autologous CAR-T therapy.
Eligibility review & medical fitness
Collection of the patient’s T cells
Genetic engineering & expansion
Short chemotherapy before infusion
CAR-T cells returned to the patient
CRS, neurologic events & recovery
Why CAR-T is considered a major advance
In selected relapsed or refractory B-cell malignancies, CAR-T therapy has demonstrated high rates of complete response and the possibility of long-term disease control in a subset of patients.
High response rates
In large B-cell lymphoma after multiple prior lines, modern CD19 CAR-T products have reported objective response rates frequently above 50–70% in pivotal studies.
Potential for durability
A meaningful minority of patients maintain long-term remissions — some remaining progression-free for years after a single infusion.
One-time treatment model
Most current approaches involve a single infusion (preceded by short lymphodepletion), followed by monitoring and supportive care.
Note: Results vary by product, disease subtype, prior therapy and patient selection. Serious toxicities (CRS, neurologic events, prolonged cytopenias, infections) can occur and require specialized management.
Global access & approximate costs
Commercial CAR-T products are available in several major markets. Figures below refer mainly to product list prices or reported episode-of-care estimates and vary by country, indication and reimbursement.
| Region | Status | Approx. cost range* |
|---|---|---|
| United States | Fully approved commercial | USD 373k – 475k+ |
| Western Europe | Approved & reimbursed | €250k – €400k+ |
| Japan | Approved commercial | High (comparable to West) |
| South Korea | Approved commercial | Lower than typical US/EU |
| China | Multiple approved + trials | Generally lower than West |
*Approximate ranges. Actual cost depends on insurance, hospital fees, toxicity management and individual circumstances.
Current situation of CAR-T in Türkiye
Until recently, access has been limited and often dependent on referral abroad or high-cost importation. Local manufacturing capability is now emerging through technology transfer and domestic development.
Biruni Cell Therapy (BCT)
Establishing local GMP manufacturing of Anbal-cel (anbalcabtagene autoleucel) through technology transfer from Curocell (South Korea). Anbal-cel is a CD19-directed CAR-T that already received MFDS approval in South Korea (2026) for certain relapsed/refractory large B-cell lymphomas — one of the first technology-transfer routes bringing an already-approved product into local production in Türkiye.
Read more about Biruni Cell Therapy →StemBio
A Turkish cGMP cell and tissue center also active in the CAR-T field. Public information indicates development of CAR-T production capabilities and research activity. Current data place this work in the research and early-development stage rather than an approved commercial product with completed late-phase results.
Status based on publicly available information as of mid-2026.
Why Türkiye is becoming an attractive destination
Several factors are positioning Türkiye as a potential option for patients seeking CAR-T therapy, particularly when cost and logistics matter.
Reported target treatment cost range in the emerging local pathway — substantially lower than typical US list prices and many Western European episode costs.
Technology-transfer manufacturing reduces dependence on long-distance shipping of living cell products and can shorten vein-to-vein time.
The Anbal-cel pathway is based on a product that already obtained regulatory approval in South Korea, providing a clinical evidence base.
Specialized clinical centers with experience in cellular therapy, apheresis and toxicity management are developing capacity.
Cost figures are approximate. Final cost depends on product, clinical pathway, hospital fees and individual factors. Eligibility is determined by qualified physicians.
Considering CAR-T evaluation?
This educational portal offers a free medical second-opinion request service. Submit key clinical information for an initial educational review to help understand whether further evaluation may be appropriate.
Request Free Medical Second OpinionEducational service only. Not a guarantee of eligibility or treatment.